Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
28.1M
-
Shares change
-
-2.56M
-
Total reported value, excl. options
-
$1.25B
-
Value change
-
-$107M
-
Put/Call ratio
-
1.89
-
Number of buys
-
69
-
Number of sells
-
-68
-
Price
-
$44.37
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2018
200 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2018.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.1M shares
of 207M outstanding shares and own 13.56% of the company stock.
Largest 10 shareholders include BB BIOTECH AG (3.28M shares), Meditor Group Ltd (2.63M shares), Pentwater Capital Management LP (2.35M shares), Partner Fund Management, L.P. (1.97M shares), BlackRock Inc. (1.88M shares), STATE STREET CORP (1.85M shares), Vanguard Group Inc (1.65M shares), BOXER CAPITAL, LLC (1.38M shares), Aviva Holdings Ltd. (1.2M shares), and CREDIT SUISSE AG/ (971K shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.